# An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

> **NCT00274443** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 250 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** ABI-007 (Abraxane) and Carboplatin

## Key facts

- **NCT ID:** NCT00274443
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-01
- **Primary completion:** 2007-06-01
- **Final completion:** 2007-06-01
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274443, "An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00274443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*